Abstract library

24 results for "Carmona".
#950 Outcome of Malignant Insulinomas (MI) in the Community Setting
Introduction: MI is a rare and difficult to handle functional pancreatic neuroendocrine tumor with a variety of therapeutic alternatives.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: MD Carlos Lopez Lopez
#1011 Predictive Factors for Progression Free Survival (PFS) in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNET) Treated with Sunitinib
Introduction: Sunitinib and everolimus were approved for treatment of progressive PNET based on phase III trial data. However, features that may influence outcome with these antitargets have not been well-established.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
#1026 Systemic Therapy in Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) and Ki Index 5-10%
Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
#1116 Streptozotocin Based Chemotherapy in Advanced G2 Pancreatic Neuroendocrine Tumors (PNET): Efficacy According to KI67 Index
Introduction: Streptozotocin (STZ) with fluorouracil (FU) or doxorubicin (DOX) is approved in well differentiated advanced pancreatic neuroendocrine tumors (PNET).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: PhD Paula Jiménez-Fonseca
#1133 Prognosis of Stage IV Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) According to the WHO Classification and the Primary Tumor Location
Introduction: WHO classification of GEP-NET is used to predict prognosis, yet survival within each grade shows wide variation. We hypothesized that primary tumor location may be partially responsible of this variability.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: PhD Paula Jiménez-Fonseca
#1153 Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
#1213 Everolimus (EVE)-Induced Hyperglycemia (HG) in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs): Clinical Relevance and Predictive Value
Introduction: EVE-induced HG can be explained by a decrease in insulin release or increase in peripheral insulin resistance. It has been documented in 12-13% of NET pts included in phase III clinical trials based on investigators reports.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
#1247 Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib
Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula Jiménez-Fonseca
Keywords: sunitinib, PNET, Choi, RECIST
#1389 Capecitabine and Temozolomide in NETs G1-2: The Experience of Various Hospitals in Spain
Introduction: Treatment of neuroendocrine tumors (NETs) with capecitabine-temozolomide (CAPTEM) is an option yet to be confirmed in phase III trials.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero
#1405 Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms
Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.